Down syndrome (DS) is a common genetic disorder resulting from an extra copy of genetic material from all or part of chromosome 21. Individuals with DS have a higher burden of co-occurring structural birth defects, neurocognitive delay, and chronic health conditions when compared to those without DS, as well as a 10 to 20-fold excess risk for acute leukemia (AL). Few studies have reported the late effects of cancer treatment in DS-AL survivors, and even fewer have compared outcomes to children with DS and no cancer history. The Children’s Oncology Group study ALTE22C1 was developed to address this knowledge gap.
Kids First Partner Institutions
facebook
BlueskyLinkedIninstgramyoutubeFollow @kidsfirstdrc EMAIL KIDS FIRST Privacy Policy Cookies
The Kids First Data Resource Center (“DRC”) comprises partnered institutions supported by the NIH Common Fund under Award Number U2CHL138346 as part of the Common Fund’s Gabriella Miller Kids First Pediatric Research Program (“Kids First”). All content, terms and conditions and policies associated with the DRC Portal and Website (the “Services”) are produced by the DRC. The views and opinions of authors expressed on the Services do not necessarily state or reflect those of the National Institutes of Health (“NIH”) or the U.S. government. Furthermore, the NIH does not endorse or promote any DRC entity or any of its products or services nor guarantees the products, services, or information provided by the DRC.
© 2026 Gabriella Miller Kids First Data Resource Center. All rights reserved.